Semaglutide could be a game-changer for patients with HFpEF and obesity

Semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared with placebo in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.

Research reveals transgenerational effects of adversity on the human gut microbiome

Hardship experienced by mothers during their own childhood or during pregnancy is reflected in the composition of their 2-year-old children’s gut microbiomes, reports an international

July 21, 2023

Climate change: A growing threat to emergency response

International experts in emergency medicine have warned that climate change is likely to have a severe impact on emergency services around the world. Despite this,

October 14, 2024

IMS-001 by Imstem Biotechnology for Secondary Progressive Multiple Sclerosis (SPMS): Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

February 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.